Trial Profile
Belatacept Immunosuppression Therapy in Post-Transplant Kidney Recipients: Comparison of 4-Week and 8-Week Dosing Intervals
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 14 Feb 2021 Results published in the American Journal of Transplantation
- 03 Jun 2020 Results presented at the 2020 American Transplant Congress.
- 16 Oct 2019 Status changed from active, no longer recruiting to completed.